Personalis
Personalis Cuts 65 Jobs in Continued Cost-Reduction Effort
The company said that it believes the layoffs affect 20 percent of its workforce and will lead to savings of about $14 million for fiscal year 2024.
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy assay while Personalis completes its clinical validation in more indications.
In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium
The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.
Personalis Sues Foresight Diagnostics Again Alleging Patent Infringement
The move brings the number of patents that the company alleges its rival is infringing to seven, with two of the initial four currently under inter partes review.
Liquid Biopsy Firms Eye Melanoma for Minimal Residual Disease Testing, Though Questions Remain
Premium
MRD assays show promise in immunotherapy response prediction with the potential to guide dose/treatment escalation with emerging adjuvant approaches.